文献速递免疫规划

小鼠腺病毒载体免疫持久性及其对疫苗效力的影响

Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy.
PubMed 文献 · Vaccine · 2018-09-25

研究探讨腺病毒载体免疫在小鼠体内是否随时间下降至足以支持每年接种同一载体疫苗。HAdV-C5预免疫或未免疫小鼠接种HAd-GFP后1、3、6、10个月再接种HAd-H5HA,载体免疫持续显著下降,HA特异性体液和细胞免疫应答持续显著上升,预免疫动物在6个月及以后对异源H5N1攻击的保护效力显著改善。

要点

  • 载体免疫随时间持续显著下降,HA特异性免疫应答持续显著上升。
  • 预免疫动物在6个月及以后对异源H5N1攻击的保护效力显著改善。
  • 每年接种同一腺病毒载体疫苗可能有效。

核心结论

  • 由于载体免疫显著下降,每年免疫接种同一AdV载体可能是有效的。

研究设计与样本

  • 用HAdV-C5载体表达GFP(HAd-GFP)以108 PFU肌内接种模拟首次接种,在接种后1、3、6、10个月用表达H5N1血凝素的HAd-H5HA以108 PFU肌内接种未免疫或HAdV预免疫小鼠。

主要发现

  • 载体免疫滴度随时间显著持续下降。
  • HA特异性体液和细胞介导免疫应答水平显著持续上升。
  • HAdV预免疫动物在6个月及以后对抗原性异源H5N1病毒攻击的保护效力显著改善。

临床怎么用

  • 原文提示每年接种同一AdV载体可能有效,因载体免疫显著下降。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a high incidence of adenovirus (AdV) infection in humans due to the presence of more than 60 types of human adenoviruses (HAdVs). The majority of individuals are exposed to one or more HAdV types early in their lives, leading to the development of AdV type-specific neutralizing antibodies. Similarly, immunization or gene therapy with AdV vectors leads to immune responses to the AdV vector. This 'vector immunity' is a concern for AdV vector-based applications for vaccines or gene therapy, especially when the repeated administration of a vector is required. The objective of this investigation was to establish whether AdV neutralizing antibody titers decline sufficiently in a year to permit annual vaccination with the same AdV vector. Naïve or human adenoviral vector group C, type 5 (HAdV-C5)-primed mice were mock-inoculated (with PBS) or inoculated i.m. with 108 PFU of either HAd-GFP [HAdV-C5 vector expressing the green fluorescent protein (GFP)] to mimic the conditions for the first inoculation with an AdV vector-based vaccine. At 1, 3, 6, and 10 months post-HAd-GFP inoculation, naïve- or HAdV-primed animals were vaccinated i.m. with 108 PFU of HAd-H5HA [HAdV-C5 vector expressing hemagglutinin (HA) of H5N1 influenza virus]. There was a significant continual decrease in vector immunity titers with time, thereby leading to significant continual increases in the levels of HA-specific humoral and cell-mediated immune responses. In addition, significant improvement in protection efficacy against challenge with an antigenically heterologous H5N1 virus was observed in HAdV-primed animals at 6 months and onwards. These results indicate that the annual immunization with the same AdV vector may be effective due to a significant decline in vector immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sayedahmed EE, Kumari R, Shukla S, et al. Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy. Vaccine. 2018. PMID: 30266488. doi:10.1016/j.vaccine.2018.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。